PPIDT00040
Drug Information
| Name | Omalizumab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB00043 |
| Type | biotech |
| Indication | Omalizumab is indicated for: - the treatment of patients six years of age and older with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.[L50477, L50482] - add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults with inadequate response to nasal corticosteroids.[L50477, L50482] - the reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods in patients aged one year and older with IgE-mediated food allergy. Omalizumab is to be used in conjunction with food allergen avoidance.[L50477] - the treatment of adults and adolescents 12 years of age and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment.[L50477] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Subcutaneous |
150 MG
|
| Injection, powder, for solution | Subcutaneous |
150 MG
|
| Injection, powder, for solution | Subcutaneous |
75 MG
|
| Injection, solution | Parenteral; Subcutaneous |
150 MG
|
| Injection, solution | Parenteral; Subcutaneous |
300 mg
|
| Injection, solution | Parenteral; Subcutaneous |
75 MG
|
| Injection, solution | Subcutaneous |
150 mg/1.2mL
|
| Injection, solution | Subcutaneous |
300 mg/2mL
|
| Injection, solution | Subcutaneous |
300 mg
|
| Injection, solution | Subcutaneous |
75 mg
|
| Powder | — |
150 mg/1vial
|
| Powder, for solution | Subcutaneous |
150 mg / vial
|
| Solution | Subcutaneous |
150 mg / mL
|
| Solution | Subcutaneous |
150 mg / 1 mL
|
| Solution | Subcutaneous |
300 mg / 2 mL
|
| Solution | Subcutaneous |
75 mg / 0.5 mL
|
| Solution | Subcutaneous |
75.000 mg
|
| Injection, powder, for solution | Subcutaneous |
15000000 mg
|
| Solution | Subcutaneous |
15000000 mg
|
| Solution | Subcutaneous |
7500000 mg
|
| Injection, solution | Subcutaneous |
150 mg
|
| Injection, solution | Subcutaneous |
150 mg/ml
|
| Injection, powder, lyophilized, for solution | Subcutaneous |
150 mg
|
| Solution | Subcutaneous |
150 mg/ml
|
| Injection, powder, lyophilized, for solution | Subcutaneous |
75 mg
|
| Solution | Subcutaneous |
75 mg/0.5ml
|
| Injection, solution | Subcutaneous |
150 mg/1mL
|
| Injection, solution | Subcutaneous |
75 mg/0.5mL
|
| Injection, solution | Subcutaneous |
150 mg/1.0mL
|